Site icon pharmaceutical daily

NeoGenomics Reports Fourth Quarter and Full Year 2023 Results

Fourth Quarter Revenue Increased 12% to $156 million;

Full Year Revenue Increased 16% to $592 million

FORT MYERS, Fla.–(BUSINESS WIRE)–NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2023 results for the period ended December 31, 2023.


Highlights

“NeoGenomics’ fourth quarter and full year 2023 results show the momentum and strength of our business as we continued to deliver long-term, sustainable growth on our way to becoming the leading oncology laboratory,” said Chris Smith, CEO of NeoGenomics. “We believe 2024 will be an exciting year as we continue to invest in our people and technologies to support consistent revenue growth and profitability, while allowing us to better serve our patients and providers.”

Fourth Quarter Results

Consolidated revenue for the fourth quarter of 2023 was $156 million, an increase of 12% over the same period in 2022. Clinical Services revenue of $130 million was an increase year-over-year of 20%. Clinical test volume(1) increased by 6% year-over-year. Average revenue per clinical test (“revenue per test”) increased by 13% to $441. Advanced Diagnostics revenue decreased by 17% to $25 million compared to the fourth quarter of 2022.

Consolidated gross profit for the fourth quarter of 2023 was $67.6 million, an increase of 18.9% compared to the fourth quarter of 2022. This increase was primarily due to an increase in revenue. Consolidated gross profit margin, including amortization of acquired intangible assets, was 43.5%. Adjusted Gross Profit Margin(2), excluding amortization of acquired intangible assets, was 46.7%.

Operating expenses for the fourth quarter of 2023 were $86 million, an increase of $3 million, or 4%, compared to the fourth quarter of 2022. This increase primarily reflects an increase in professional fees, an increase in payroll and payroll-related costs, including non-cash stock-based compensation expense, and an increase in travel expenses. This increase was partially offset by a decrease in recruiting expenses and a decrease in credit card fees.

Net loss for the quarter was $14 million compared to net loss of $23 million for the fourth quarter of 2022.

Adjusted EBITDA(2) was positive $9 million compared to negative $1 million in the fourth quarter of 2022. Adjusted Net Income(2) was $4 million compared to Adjusted Net Loss(2) of $7 million in the fourth quarter of 2022.

Cash and cash equivalents and marketable securities totaled $415 million at quarter end.

Full Year Results

Consolidated revenue for 2023 was $592 million, an increase of 16% over 2022. This increase was primarily driven by an increase in test volume, a more favorable test mix in our Clinical Services segment, an increase in average unit price due to strategic reimbursement initiatives, and growth in our Advanced Diagnostics segment, primarily due by increased volume and higher billings across its portfolio. Net loss for 2023 was $88 million compared to net loss of $144 million in 2022. Adjusted EBITDA(2) for 2023 was positive $3 million compared to negative $48 million in 2022. Adjusted net loss(2) for 2023 was $15 million compared to adjusted net loss of $70 million in 2022.

2024 Financial Guidance

The Company also issued 2024 guidance(3) today (in millions).

 

 

FY 2023

 

FY 2024 Guidance

 

YOY % Change from FY 2023

 

 

Actual

 

Low

 

High

 

Low

 

High

Consolidated revenue

 

$592

 

$650

 

$660

 

10%

 

12%

Net loss

 

$(88)

 

$(72)

 

$(66)

 

18%

 

25%

Adjusted EBITDA

 

$3

 

$21

 

$24

 

600%

 

700%

(1)

Clinical testing excludes requisitions, tests, revenue and costs of revenue for Advanced Diagnostics.

(2)

The Company has provided adjusted financial information that has not been prepared in accordance with GAAP, including Adjusted EBITDA, Adjusted Gross Profit Margin, Adjusted Net Loss, and Adjusted Diluted EPS. Each of these measures is defined in the section of this report entitled “Use of Non-GAAP Financial Measures.” See also the tables reconciling such measures to their closest GAAP equivalent.

(3)

The Company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan. Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company’s securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance.

Conference Call

The Company has scheduled a webcast and conference call to discuss its fourth quarter and full year 2023 results on Tuesday, February 20, 2024 at 4:30 PM EDT. Interested investors should dial (888) 506-0062 (domestic) and (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 822624. The webcast will be archived and available for replay shortly after the conclusion of the call. It may be accessed under the Investor Relations section of our website at ir.neogenomics.com.

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development.

NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.

Forward Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “plan,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company’s ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company’s other filings with the Securities and Exchange Commission.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

NeoGenomics, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited, in thousands)

 

 

 

As of December 31,

 

 

2023

 

2022

ASSETS

 

 

 

 

Current Assets

 

 

 

 

Cash and cash equivalents

 

$

342,488

 

$

263,180

Marketable securities, at fair value

 

 

72,715

 

 

 

174,809

 

Accounts receivable, net

 

 

131,227

 

 

 

119,711

 

Inventories

 

 

24,156

 

 

 

24,277

 

Prepaid assets

 

 

17,987

 

 

 

15,237

 

Other current assets

 

 

8,239

 

 

 

8,077

 

Total current assets

 

 

596,812

 

 

 

605,291

 

Property and equipment (net of accumulated depreciation of $158,211 and $131,930, respectively)

 

 

92,012

 

 

 

102,499

 

Operating lease right-of-use assets

 

 

91,769

 

 

 

96,109

 

Intangible assets, net

 

 

373,128

 

 

 

408,260

 

Goodwill

 

 

522,766

 

 

 

522,766

 

Other assets

 

 

4,742

 

 

 

5,109

 

Total non-current assets

 

 

1,084,417

 

 

 

1,134,743

 

Total assets

 

$

1,681,229

 

 

$

1,740,034

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

Current liabilities

 

 

 

 

Accounts payable and other current liabilities

 

$

90,694

 

 

$

83,278

 

Current portion of equipment financing obligations

 

 

 

 

 

70

 

Current portion of operating lease liabilities

 

 

5,610

 

 

 

6,584

 

Total current liabilities

 

 

96,304

 

 

 

89,932

 

Long-term liabilities

 

 

 

 

Convertible senior notes, net

 

 

538,198

 

 

 

535,322

 

Operating lease liabilities

 

 

67,871

 

 

 

68,952

 

Deferred income tax liabilities, net

 

 

24,285

 

 

 

34,750

 

Other long-term liabilities

 

 

13,034

 

 

 

13,055

 

Total long-term liabilities

 

 

643,388

 

 

 

652,079

 

Total liabilities

 

 

739,692

 

 

 

742,011

 

Stockholders’ equity

 

 

 

 

Total stockholders’ equity

 

 

941,537

 

 

 

998,023

 

Total liabilities and stockholders’ equity

 

$

1,681,229

 

 

$

1,740,034

 

NeoGenomics, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, in thousands, except per share amounts)

 

 

 

Three Months Ended

December 31,

 

Years Ended December 31,

 

 

2023

 

2022

 

2023

 

2022

NET REVENUE

 

 

 

 

 

 

 

 

Clinical Services

 

$

130,058

 

 

$

108,166

 

 

$

495,636

 

 

$

418,754

 

Advanced Diagnostics

 

 

25,494

 

 

 

30,539

 

 

 

96,007

 

 

 

90,974

 

Total net revenue

 

 

155,552

 

 

 

138,705

 

 

 

591,643

 

 

 

509,728

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

87,964

 

 

 

81,880

 

 

 

347,039

 

 

 

321,832

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

67,588

 

 

 

56,825

 

 

 

244,604

 

 

 

187,896

 

Operating expenses:

 

 

 

 

 

 

 

 

General and administrative

 

 

59,758

 

 

 

57,855

 

 

 

243,101

 

 

 

243,356

 

Research and development

 

 

7,127

 

 

 

6,675

 

 

 

27,309

 

 

 

30,326

 

Sales and marketing

 

 

18,072

 

 

 

17,142

 

 

 

70,842

 

 

 

67,321

 

Restructuring charges

 

 

1,205

 

 

 

1,536

 

 

 

11,088

 

 

 

4,516

 

Total operating expenses

 

 

86,162

 

 

 

83,208

 

 

 

352,340

 

 

 

345,519

 

LOSS FROM OPERATIONS

 

 

(18,574

)

 

 

(26,383

)

 

 

(107,736

)

 

 

(157,623

)

Interest income

 

 

(4,845

)

 

 

(2,677

)

 

 

(16,902

)

 

 

(6,075

)

Interest expense

 

 

1,681

 

 

 

1,817

 

 

 

6,907

 

 

 

7,581

 

Other expense (income), net

 

 

(124

)

 

 

1

 

 

 

(644

)

 

 

213

 

Loss before taxes

 

 

(15,286

)

 

 

(25,524

)

 

 

(97,097

)

 

 

(159,342

)

Income tax benefit

 

 

(960

)

 

 

(2,837

)

 

 

(9,129

)

 

 

(15,092

)

NET LOSS

 

$

(14,326

)

 

$

(22,687

)

 

$

(87,968

)

 

$

(144,250

)

 

 

 

 

 

 

 

 

 

NET LOSS PER SHARE

 

 

 

 

 

 

 

 

Basic

 

$

(0.11

)

 

$

(0.18

)

 

$

(0.70

)

 

$

(1.16

)

Diluted

 

$

(0.11

)

 

$

(0.18

)

 

$

(0.70

)

 

$

(1.16

)

 

 

 

 

 

 

 

 

 

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING

 

 

 

 

 

 

 

 

Basic

 

 

125,929

 

 

 

124,714

 

 

 

125,502

 

 

 

124,217

 

Diluted

 

 

125,929

 

 

 

124,714

 

 

 

125,502

 

 

 

124,217

 

NeoGenomics, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)

 

 

 

Years Ended December 31,

 

 

2023

 

2022

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

Net loss

 

$

(87,968

)

 

$

(144,250

)

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

 

 

Depreciation

 

 

37,450

 

 

 

35,372

 

Amortization of intangibles

 

 

35,133

 

 

 

34,058

 

Non-cash stock-based compensation

 

 

24,633

 

 

 

24,672

 

Non-cash operating lease expense

 

 

9,235

 

 

 

9,775

 

Amortization of convertible debt discount and debt issue costs

 

 

2,876

 

 

 

2,839

 

Loss on disposal of assets

 

 

292

 

 

 

2,858

 

Gain on sale of assets held for sale

 

 

 

 

 

(2,048

)

Impairment of long-lived assets

 

 

1,703

 

 

 

718

 

Other adjustments

 

 

186

 

 

 

1,714

 

Changes in assets and liabilities, net:

 

 

(25,493

)

 

 

(31,701

)

Net cash used in operating activities

 

$

(1,953

)

 

$

(65,993

)

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

Purchases of marketable securities

 

 

(6,756

)

 

 

(97,605

)

Proceeds from sales and maturities of marketable securities

 

 

112,215

 

 

 

116,915

 

Purchases of property and equipment

 

 

(28,752

)

 

 

(30,891

)

Proceeds from assets held for sale

 

 

 

 

 

12,098

 

Net cash provided by investing activities

 

$

76,707

 

 

$

517

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

Repayment of equipment financing obligations

 

 

(70

)

 

 

(758

)

Issuance of common stock, net

 

 

4,624

 

 

 

12,587

 

Net cash provided by financing activities

 

$

4,554

 

 

$

11,829

 

Net change in cash and cash equivalents

 

$

79,308

 

 

$

(53,647

)

 

 

 

 

 

Cash and cash equivalents, beginning of year

 

 

263,180

 

 

 

316,827

 

Cash, cash equivalents and restricted cash, end of year

 

$

342,488

 

 

$

263,180

 

Use of Non-GAAP Financial Measures

In order to provide greater transparency regarding our operating performance, the financial results and financial guidance in this press release refer to certain non-GAAP financial measures that involve adjustments to GAAP results. Non-GAAP financial measures exclude certain income and/or expense items that management believes are not directly attributable to the Company’s core operating results and/or certain items that are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. Management believes that the presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors by facilitating the analysis of the Company’s core test-level operating results across reporting periods and when comparing those same results to those published by our peers. These non-GAAP financial measures may also assist investors in evaluating future prospects. Management also uses non-GAAP financial measures for financial and operational decision making, planning and forecasting purposes and to manage the business. These non-GAAP financial measures do not replace the presentation of financial information in accordance with U.S. GAAP financial results, should not be considered measures of liquidity, and are unlikely to be comparable to non-GAAP financial measures provided by other companies.

Definitions of Non-GAAP Measures

Non-GAAP Adjusted EBITDA

“Adjusted EBITDA” is defined by NeoGenomics as net (loss) income from continuing operations before: (i) interest income and expense, (ii) tax (benefit) or expense, (iii) depreciation and amortization expense, (iv) non-cash stock-based compensation expense, and, if applicable in a reporting period, (v) acquisition and integration related expenses, (vi) CEO transition costs, (vii) restructuring costs, and (viii) other significant or non-operating expenses, net.

Non-GAAP Adjusted Cost of Revenue, Adjusted Gross Profit and Adjusted Gross Profit Margin

“Adjusted cost of revenue” is defined by NeoGenomics as cost of revenue before amortization expense of acquired intangible assets.

“Adjusted gross profit” is defined by NeoGenomics as total revenue less adjusted cost of revenue.

“Adjusted gross profit margin” is defined by NeoGenomics as adjusted cost of revenue divided by total revenue.

Non-GAAP Adjusted Net (Loss) Income

“Adjusted net (loss) income” is defined by NeoGenomics as net (loss) income from continuing operations plus: (i) non-cash amortization of intangible assets, (ii) non-cash stock-based compensation expense, and, if applicable in a reporting period, (iii) acquisition and integration related expenses, (iv) CEO transition costs, (v) restructuring costs, and (vi) other significant or non-operating expenses, net. If GAAP net (loss) income is negative and adjusted net (loss) income is positive, adjusted net (loss) income will also be adjusted to reverse any recognized interest expense (including any amortization of discounts) on the convertible notes using the if-converted method unless the effect of this adjustment on both the adjusted net (loss) income and weighted average diluted common shares outstanding would be anti-dilutive. If GAAP net (loss) income is positive and adjusted net (loss) income is negative, adjusted net (loss) income will also be adjusted to reverse any recognized interest expense (including any amortization of discounts) on the convertible notes using the if-converted method.

Non-GAAP Adjusted Diluted EPS

“Adjusted diluted EPS” is defined by NeoGenomics as adjusted net (loss) income divided by adjusted diluted shares outstanding. If GAAP net (loss) income is negative and adjusted net (loss) income is positive, adjusted diluted shares outstanding will also include any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive. If GAAP net (loss) income is positive and adjusted net (loss) income is negative, adjusted diluted shares outstanding will exclude any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period.

Reconciliation of GAAP Net Loss to Non-GAAP EBITDA and Adjusted EBITDA

(Unaudited, in thousands)

 

 

Three Months Ended

December 31,

 

Years Ended December 31,

 

2023

 

2022

 

2023

 

2022

Net loss (GAAP)

$

(14,326

)

 

$

(22,687

)

 

$

(87,968

)

 

$

(144,250

)

Adjustments to net loss:

 

 

 

 

 

 

 

Interest income

 

(4,845

)

 

 

(2,677

)

 

 

(16,902

)

 

 

(6,075

)

Interest expense

 

1,681

 

 

 

1,817

 

 

 

6,907

 

 

 

7,581

 

Income tax benefit

 

(960

)

 

 

(2,837

)

 

 

(9,129

)

 

 

(15,092

)

Depreciation

 

9,578

 

 

 

9,478

 

 

 

37,450

 

 

 

35,372

 

Amortization of intangibles

 

8,783

 

 

 

8,588

 

 

 

35,133

 

 

 

34,058

 

EBITDA (non-GAAP)

 

(89

)

 

 

(8,318

)

 

 

(34,509

)

 

 

(88,406

)

Further adjustments to EBITDA:

 

 

 

 

 

 

 

Acquisition and integration related expenses

 

 

 

 

 

 

 

 

 

 

2,479

 

CEO transition costs

 

 

 

 

 

 

 

500

 

 

 

4,518

 

Non-cash stock-based compensation expense

 

6,990

 

 

 

4,662

 

 

 

24,633

 

 

 

24,672

 

Restructuring charges

 

1,205

 

 

 

1,536

 

 

 

11,088

 

 

 

4,516

 

Other significant expenses (income), net(4)

 

1,242

 

 

 

952

 

 

 

1,774

 

 

 

4,211

 

Adjusted EBITDA (non-GAAP)

$

9,348

 

 

$

(1,168

)

 

$

3,486

 

 

$

(48,010

)

_________________

(4)

For the three months ended December 31, 2023, other significant (income) expenses, net, includes fees related to a regulatory matter and other non-recurring items. For the three months ended December 31, 2022, other significant (income) expenses, net, includes fees related to a regulatory matter and other non-recurring items. For the year ended December 31, 2023, other significant (income) expenses, net, includes fees related to a regulatory matter and other non-recurring items. For the year ended December 31, 2022, other significant (income) expenses, net, includes fees related to a regulatory matter, moving costs, a gain on the sale of a building and other non-recurring items.

Reconciliation of Segment and Consolidated GAAP Cost of Revenue, Gross Profit and Gross Profit Margin to

Non-GAAP Adjusted Cost of Revenue, Adjusted Gross Profit and Adjusted Gross Profit Margin

(Unaudited, dollars in thousands)

 

 

 

Three Months Ended December 31,

 

Years Ended December 31,

 

 

2023

 

2022

 

% Change

 

2023

 

2022

 

% Change

Clinical Services:

 

 

 

 

 

 

 

 

 

 

 

 

Total revenue (GAAP)

 

$

130,058

 

 

$

108,166

 

 

20.2

%

 

$

495,636

 

 

$

418,754

 

 

18.4

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue (GAAP)

 

$

74,027

 

 

$

64,180

 

 

15.3

%

 

$

287,059

 

 

$

261,742

 

 

9.7

%

Adjustments to cost of revenue(5)

 

 

(4,489

)

 

 

(4,264

)

 

 

 

 

(17,280

)

 

 

(17,054

)

 

 

Adjusted cost of revenue (non-GAAP)

 

$

69,538

 

 

$

59,916

 

 

16.1

%

 

$

269,779

 

 

$

244,688

 

 

10.3

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit (GAAP)

 

$

56,031

 

 

$

43,986

 

 

27.4

%

 

$

208,577

 

 

$

157,012

 

 

32.8

%

Adjusted gross profit (non-GAAP)

 

$

60,520

 

 

$

48,250

 

 

25.4

%

 

$

225,857

 

 

$

174,066

 

 

29.8

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit margin (GAAP)

 

 

43.1

%

 

 

40.7

%

 

 

 

 

42.1

%

 

 

37.5

%

 

 

Adjusted gross profit margin (non-GAAP)

 

 

46.5

%

 

 

44.6

%

 

 

 

 

45.6

%

 

 

41.6

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Advanced Diagnostics:

 

 

 

 

 

 

 

 

 

 

 

 

Total revenue (GAAP)

 

$

25,494

 

 

$

30,539

 

 

(16.5

)%

 

$

96,007

 

 

$

90,974

 

 

5.5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue (GAAP)

 

$

13,937

 

 

$

17,700

 

 

(21.3

)%

 

$

59,980

 

 

$

60,090

 

 

(0.2

)%

Adjustments to cost of revenue(6)

 

 

(590

)

 

 

(590

)

 

 

 

 

(2,358

)

 

 

(2,358

)

 

 

Adjusted cost of revenue (non-GAAP)

 

$

13,347

 

 

$

17,110

 

 

(22.0

)%

 

$

57,622

 

 

$

57,732

 

 

(0.2

)%

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit (GAAP)

 

$

11,557

 

 

$

12,839

 

 

(10.0

)%

 

$

36,027

 

 

$

30,884

 

 

16.7

%

Adjusted gross profit (non-GAAP)

 

$

12,147

 

 

$

13,429

 

 

(9.5

)%

 

$

38,385

 

 

$

33,242

 

 

15.5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit margin (GAAP)

 

 

45.3

%

 

 

42.0

%

 

 

 

 

37.5

%

 

 

33.9

%

 

 

Adjusted gross profit margin (non-GAAP)

 

 

47.6

%

 

 

44.0

%

 

 

 

 

40.0

%

 

 

36.5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated:

 

 

 

 

 

 

 

 

 

 

 

 

Total revenue (GAAP)

 

$

155,552

 

 

$

138,705

 

 

12.1

%

 

$

591,643

 

 

$

509,728

 

 

16.1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue (GAAP)

 

$

87,964

 

 

$

81,880

 

 

7.4

%

 

$

347,039

 

 

$

321,832

 

 

7.8

%

Adjustments to cost of revenue(5)(6)

 

 

(5,079

)

 

 

(4,854

)

 

 

 

 

(19,638

)

 

 

(19,412

)

 

 

Adjusted cost of revenue (non-GAAP)

 

$

82,885

 

 

$

77,026

 

 

7.6

%

 

$

327,401

 

 

$

302,420

 

 

8.3

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit (GAAP)

 

$

67,588

 

 

$

56,825

 

 

18.9

%

 

$

244,604

 

 

$

187,896

 

 

30.2

%

Adjusted gross profit (non-GAAP)

 

$

72,667

 

 

$

61,679

 

 

17.8

%

 

$

264,242

 

 

$

207,308

 

 

27.5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit margin (GAAP)

 

 

43.5

%

 

 

41.0

%

 

 

 

 

41.3

%

 

 

36.9

%

 

 

Adjusted gross profit margin (non-GAAP)

 

 

46.7

%

 

 

44.5

%

 

 

 

 

44.7

%

 

 

40.7

%

 

 

Contacts

NeoGenomics, Inc.
Kendra Sweeney

Vice President, Investor Relations and ESG

kendra.sweeney@neogenomics.com
T: +1-239-877-7474

Read full story here

Exit mobile version